![](https://static.scientificamerican.com/sciam/cache/file/A57FF64E-8937-4703-98F5545AD8E3D756_agenda.jpg?w=275&h=154&fit=crop)
New Coronavirus Drug Shows Promise in Animal Tests
Slated for human trials, EIDD-2801 could become the first pill for COVID-19
Journalist Michael Waldholz led a team of reporters who were awarded a Pulitzer Prize in 1997 for their coverage of AIDS. He lives in New York State’s Hudson Valley. Credit: Nick Higgins
Slated for human trials, EIDD-2801 could become the first pill for COVID-19
Many new drugs trigger an immune reaction that cripples them—and the race is on to thwart the attack
Bacteria face trade-offs when optimizing traits involved in antibiotic resistance
By reprogramming DNA inside harmful microbes, biologists are turning them into patient-saving drugs
With no time to make treatments from scratch, researchers search for existing compounds that deflect harm
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account